Accéder au contenu
Merck

Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.

Biomaterials (2018-02-09)
Xin Cui, Renee-Tyler Tan Morales, Weiyi Qian, Haoyu Wang, Jean-Pierre Gagner, Igor Dolgalev, Dimitris Placantonakis, David Zagzag, Luisa Cimmino, Matija Snuderl, Raymond H W Lam, Weiqiang Chen
RÉSUMÉ

Glioblastoma (GBM) is the most lethal primary adult brain tumor and its pathology is hallmarked by distorted neovascularization, diffuse tumor-associated macrophage infiltration, and potent immunosuppression. Reconstituting organotypic tumor angiogenesis models with biomimetic cell heterogeneity and interactions, pro-/anti-inflammatory milieu and extracellular matrix (ECM) mechanics is critical for preclinical anti-angiogenic therapeutic screening. However, current in vitro systems do not accurately mirror in vivo human brain tumor microenvironment. Here, we engineered a three-dimensional (3D), microfluidic angiogenesis model with controllable and biomimetic immunosuppressive conditions, immune-vascular and cell-matrix interactions. We demonstrate in vitro, GL261 and CT-2A GBM-like tumors steer macrophage polarization towards a M2-like phenotype for fostering an immunosuppressive and proangiogenic niche, which is consistent with human brain tumors. We distinguished that GBM and M2-like immunosuppressive macrophages promote angiogenesis, while M1-like pro-inflammatory macrophages suppress angiogenesis, which we coin "inflammation-driven angiogenesis." We observed soluble immunosuppressive cytokines, predominantly TGF-β1, and surface integrin (αvβ3) endothelial-macrophage interactions are required in inflammation-driven angiogenesis. We demonstrated tuning cell-adhesion receptors using an integrin (αvβ3)-specific collagen hydrogel regulated inflammation-driven angiogenesis through Src-PI3K-YAP signaling, highlighting the importance of altered cell-ECM interactions in inflammation. To validate the preclinical applications of our 3D organoid model and mechanistic findings of inflammation-driven angiogenesis, we screened a novel dual integrin (αvβ3) and cytokine receptor (TGFβ-R1) blockade that suppresses GBM tumor neovascularization by simultaneously targeting macrophage-associated immunosuppression, endothelial-macrophage interactions, and altered ECM. Hence, we provide an interactive and controllable GBM tumor microenvironment and highlight the importance of macrophage-associated immunosuppression in GBM angiogenesis, paving a new direction of screening novel anti-angiogenic therapies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Albumine de sérum bovin, lyophilized powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydroxyde de sodium solution, BioUltra, for molecular biology, 10 M in H2O
Sigma-Aldrich
Verteporfin, ≥94% (HPLC)
Sigma-Aldrich
Wortmannin, from Penicillium funiculosum, ≥98% (HPLC and TLC)
Sigma-Aldrich
IgG1 Isotype Control from murine myeloma, clone MOPC 21, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
LY-364947, ≥98% (HPLC)
Sigma-Aldrich
Cilengitide trifluoroacetic acid salt, ≥95% (HPLC)